DURHAM, N.C. --(BUSINESS WIRE)--May 6, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
First Quarter 2021 Net Revenue Per Bottle of $89 , up 11.3% over Fourth Quarter 2020 First Quarter 2021 Net Revenues of $23.0 Million Increased 12.9% over First Quarter 2020 Significant Progress Made Across the Pipeline Conference Call and Webcast Today, May 5 th , at 5:00 p.m. ET DURHAM, N.C.
Topline results expected in the third quarter of 2021 DURHAM, N.C. --(BUSINESS WIRE)--Apr. 29, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 19, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 30, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 11, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 11, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
